==Teva Pharma (TEVA) reported earnings on Wed 29 July 26 (b/o)

Teva raises 2026 UZEDY revenue outlook to $270–$290 million after record Q2 U.S. sales up 43% year over year

• Q2 2026 UZEDY U.S. net sales totaled $77 million, up 43% year over year , setting a quarterly record.
• Teva lifted its 2026 UZEDY revenue guidance to $270–$290 million from a prior $250–$280 million range.
• Teva also raised 2026 revenue outlooks for three key innovative brands following its Q2 2026 earnings results.